Tscan Therapeutics is trading at $0.25, up 9.29% in pre-market on October 9, with no clear company-specific announcement identified to explain the move.
- A Cellares manufacturing collaboration appeared in search results, but coverage dates it to June 3, so it is not a fresh catalyst.
- U.S. futures point higher, including the Nasdaq at +0.82%, but available evidence does not establish broader market sentiment as the cause of this move.